Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)
Background Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may impr...
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2020-09, Vol.34 (9), p.1914-1923 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1923 |
|---|---|
| container_issue | 9 |
| container_start_page | 1914 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 34 |
| creator | Lambert, J.L.W. Segaert, S. Ghislain, P.D. Hillary, T. Nikkels, A. Willaert, F. Lambert, J. Speeckaert, R. |
| description | Background
Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful.
Objective
The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis).
Methods
Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts.
Results
Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer.
Conclusion
This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions. |
| doi_str_mv | 10.1111/jdv.16683 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2434486007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4593-6feb319a49112ba8e2626ab5fb6c56acb5026ab1d853f63f62c5f963d9c526f63</originalsourceid><addsrcrecordid>eNp1Uk1vEzEQXSEQDYUDfwD52EpNa3vXzi6VkNI2fKlSIxG4WrPe2cWVdx3sTWhu_AR-ICd-Cd6kjeCAZcmemTdvnq2XJC8ZPWVxnd1W61MmZZ4-SkYsk_k4pXn6OBnRgstxUYjiIHkWwi2llDGRP00OUj4pmJjwUfJr7kH3RoMlHrVrW-wq6I3rAqmdJ2ETemyNJr1H6GOxJ6Yjy-C8gWDCEGgISFxNtMM7E3rTNTFbW2hb6J3fnJAOV95Z1xh9MlQwjnOrQCJ7C9Y0HUTSykTKCn0gRxezxfT3j5_zTzevyQXaxkBHZmtTYacx5ss4riKLvZxptTYaByHzB1XnZAm-J_z4efKkBhvwxf15mHx-O1tcvh9f37z7cDm9HutMFOlY1limrICsYIyXkCOXXEIp6lJqIUGXgg4xq3KR1jJurkVdyLQqtOAyZg6TNzve5apssdJRlwerlt604DfKgVH_VjrzVTVurSZZIXMxEKQ7AmuwQeV8adSabxu395VtFGhVouJc5ooLKjiLXUf3Y737tsLQq9YEjdZCh_GHFc_SLMslpZMIPd5BtXcheKz34hhVg4dU9JDaeihiX_39mj3ywTQRcLYDfDcWN_9nUh-vvuwo_wCZj9i9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2434486007</pqid></control><display><type>article</type><title>Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lambert, J.L.W. ; Segaert, S. ; Ghislain, P.D. ; Hillary, T. ; Nikkels, A. ; Willaert, F. ; Lambert, J. ; Speeckaert, R.</creator><creatorcontrib>Lambert, J.L.W. ; Segaert, S. ; Ghislain, P.D. ; Hillary, T. ; Nikkels, A. ; Willaert, F. ; Lambert, J. ; Speeckaert, R.</creatorcontrib><description>Background
Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful.
Objective
The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis).
Methods
Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts.
Results
Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer.
Conclusion
This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.</description><identifier>ISSN: 0926-9959</identifier><identifier>ISSN: 1468-3083</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.16683</identifier><identifier>PMID: 32791572</identifier><language>eng</language><publisher>England: Wiley-Blackwell</publisher><subject>Arthritis, Psoriatic - epidemiology ; Belgium ; Beta-Pso ; Comorbidity ; Dermatologie ; Dermatology ; Guidelines and Position Statements ; Human health sciences ; Humans ; Inflammatory, neurologic, infectious or malignant disorders ; Neoplasms - epidemiology ; Position Statement ; Psoriasis ; Psoriasis - complications ; Psoriasis - drug therapy ; Psoriasis - epidemiology ; Sciences de la santé humaine</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2020-09, Vol.34 (9), p.1914-1923</ispartof><rights>2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology</rights><rights>2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4593-6feb319a49112ba8e2626ab5fb6c56acb5026ab1d853f63f62c5f963d9c526f63</citedby><cites>FETCH-LOGICAL-c4593-6feb319a49112ba8e2626ab5fb6c56acb5026ab1d853f63f62c5f963d9c526f63</cites><orcidid>0000-0002-4497-8487 ; 0000-0001-5303-9310 ; 0000-0002-9421-3546</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.16683$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.16683$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32791572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lambert, J.L.W.</creatorcontrib><creatorcontrib>Segaert, S.</creatorcontrib><creatorcontrib>Ghislain, P.D.</creatorcontrib><creatorcontrib>Hillary, T.</creatorcontrib><creatorcontrib>Nikkels, A.</creatorcontrib><creatorcontrib>Willaert, F.</creatorcontrib><creatorcontrib>Lambert, J.</creatorcontrib><creatorcontrib>Speeckaert, R.</creatorcontrib><title>Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background
Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful.
Objective
The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis).
Methods
Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts.
Results
Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer.
Conclusion
This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.</description><subject>Arthritis, Psoriatic - epidemiology</subject><subject>Belgium</subject><subject>Beta-Pso</subject><subject>Comorbidity</subject><subject>Dermatologie</subject><subject>Dermatology</subject><subject>Guidelines and Position Statements</subject><subject>Human health sciences</subject><subject>Humans</subject><subject>Inflammatory, neurologic, infectious or malignant disorders</subject><subject>Neoplasms - epidemiology</subject><subject>Position Statement</subject><subject>Psoriasis</subject><subject>Psoriasis - complications</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - epidemiology</subject><subject>Sciences de la santé humaine</subject><issn>0926-9959</issn><issn>1468-3083</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1Uk1vEzEQXSEQDYUDfwD52EpNa3vXzi6VkNI2fKlSIxG4WrPe2cWVdx3sTWhu_AR-ICd-Cd6kjeCAZcmemTdvnq2XJC8ZPWVxnd1W61MmZZ4-SkYsk_k4pXn6OBnRgstxUYjiIHkWwi2llDGRP00OUj4pmJjwUfJr7kH3RoMlHrVrW-wq6I3rAqmdJ2ETemyNJr1H6GOxJ6Yjy-C8gWDCEGgISFxNtMM7E3rTNTFbW2hb6J3fnJAOV95Z1xh9MlQwjnOrQCJ7C9Y0HUTSykTKCn0gRxezxfT3j5_zTzevyQXaxkBHZmtTYacx5ss4riKLvZxptTYaByHzB1XnZAm-J_z4efKkBhvwxf15mHx-O1tcvh9f37z7cDm9HutMFOlY1limrICsYIyXkCOXXEIp6lJqIUGXgg4xq3KR1jJurkVdyLQqtOAyZg6TNzve5apssdJRlwerlt604DfKgVH_VjrzVTVurSZZIXMxEKQ7AmuwQeV8adSabxu395VtFGhVouJc5ooLKjiLXUf3Y737tsLQq9YEjdZCh_GHFc_SLMslpZMIPd5BtXcheKz34hhVg4dU9JDaeihiX_39mj3ywTQRcLYDfDcWN_9nUh-vvuwo_wCZj9i9</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Lambert, J.L.W.</creator><creator>Segaert, S.</creator><creator>Ghislain, P.D.</creator><creator>Hillary, T.</creator><creator>Nikkels, A.</creator><creator>Willaert, F.</creator><creator>Lambert, J.</creator><creator>Speeckaert, R.</creator><general>Wiley-Blackwell</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>Q33</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4497-8487</orcidid><orcidid>https://orcid.org/0000-0001-5303-9310</orcidid><orcidid>https://orcid.org/0000-0002-9421-3546</orcidid></search><sort><creationdate>202009</creationdate><title>Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)</title><author>Lambert, J.L.W. ; Segaert, S. ; Ghislain, P.D. ; Hillary, T. ; Nikkels, A. ; Willaert, F. ; Lambert, J. ; Speeckaert, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4593-6feb319a49112ba8e2626ab5fb6c56acb5026ab1d853f63f62c5f963d9c526f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Arthritis, Psoriatic - epidemiology</topic><topic>Belgium</topic><topic>Beta-Pso</topic><topic>Comorbidity</topic><topic>Dermatologie</topic><topic>Dermatology</topic><topic>Guidelines and Position Statements</topic><topic>Human health sciences</topic><topic>Humans</topic><topic>Inflammatory, neurologic, infectious or malignant disorders</topic><topic>Neoplasms - epidemiology</topic><topic>Position Statement</topic><topic>Psoriasis</topic><topic>Psoriasis - complications</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - epidemiology</topic><topic>Sciences de la santé humaine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lambert, J.L.W.</creatorcontrib><creatorcontrib>Segaert, S.</creatorcontrib><creatorcontrib>Ghislain, P.D.</creatorcontrib><creatorcontrib>Hillary, T.</creatorcontrib><creatorcontrib>Nikkels, A.</creatorcontrib><creatorcontrib>Willaert, F.</creatorcontrib><creatorcontrib>Lambert, J.</creatorcontrib><creatorcontrib>Speeckaert, R.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lambert, J.L.W.</au><au>Segaert, S.</au><au>Ghislain, P.D.</au><au>Hillary, T.</au><au>Nikkels, A.</au><au>Willaert, F.</au><au>Lambert, J.</au><au>Speeckaert, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>34</volume><issue>9</issue><spage>1914</spage><epage>1923</epage><pages>1914-1923</pages><issn>0926-9959</issn><issn>1468-3083</issn><eissn>1468-3083</eissn><abstract>Background
Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful.
Objective
The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis).
Methods
Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts.
Results
Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer.
Conclusion
This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.</abstract><cop>England</cop><pub>Wiley-Blackwell</pub><pmid>32791572</pmid><doi>10.1111/jdv.16683</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4497-8487</orcidid><orcidid>https://orcid.org/0000-0001-5303-9310</orcidid><orcidid>https://orcid.org/0000-0002-9421-3546</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2020-09, Vol.34 (9), p.1914-1923 |
| issn | 0926-9959 1468-3083 1468-3083 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496856 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Arthritis, Psoriatic - epidemiology Belgium Beta-Pso Comorbidity Dermatologie Dermatology Guidelines and Position Statements Human health sciences Humans Inflammatory, neurologic, infectious or malignant disorders Neoplasms - epidemiology Position Statement Psoriasis Psoriasis - complications Psoriasis - drug therapy Psoriasis - epidemiology Sciences de la santé humaine |
| title | Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A03%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Practical%20recommendations%20for%20systemic%20treatment%20in%20psoriasis%20in%20case%20of%20coexisting%20inflammatory,%20neurologic,%20infectious%20or%20malignant%20disorders%20(BETA%E2%80%90PSO:%20Belgian%20Evidence%E2%80%90based%20Treatment%20Advice%20in%20Psoriasis;%20part%202)&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Lambert,%20J.L.W.&rft.date=2020-09&rft.volume=34&rft.issue=9&rft.spage=1914&rft.epage=1923&rft.pages=1914-1923&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.16683&rft_dat=%3Cproquest_pubme%3E2434486007%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2434486007&rft_id=info:pmid/32791572&rfr_iscdi=true |